Angle PLC Announces Parsortix Enables Study Of Cancer Progression
ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company, announced a significant publication in Nature Genetics by ETH Zurich researchers utilizing the company's Parsortix® system. The study investigated genetic diversity in circulating tumor cell (CTC) clusters in breast cancer.
The research revealed that CTC clusters are up to 100 times more metastatic than individual CTCs, with metastatic spread responsible for over 90% of cancer-related deaths. The study found higher prevalence of CTC clusters in high-complexity tumors, with some mutations being exclusive to specific cells within CTC clusters that could be missed by traditional tissue biopsies.
The findings position CTC clusters as crucial targets for stopping cancer spread, highlighting Parsortix's capability to overcome spatial and temporal limitations of conventional tissue biopsy methods.
ANGLE plc (OTCQX:ANPCY), azienda leader nel campo delle biopsie liquide, ha annunciato una pubblicazione significativa su Nature Genetics realizzata da ricercatori dell'ETH di Zurigo che hanno utilizzato il sistema Parsortix® dell'azienda. Lo studio ha analizzato la diversità genetica nei cluster di cellule tumorali circolanti (CTC) nel cancro al seno.
La ricerca ha dimostrato che i cluster di CTC sono fino a 100 volte più metastatici rispetto alle singole CTC, con la diffusione metastatica responsabile di oltre il 90% dei decessi correlati al cancro. È stata riscontrata una maggiore presenza di cluster di CTC nei tumori ad alta complessità, con alcune mutazioni presenti esclusivamente in specifiche cellule all'interno dei cluster, che potrebbero sfuggire alle biopsie tissutali tradizionali.
I risultati evidenziano i cluster di CTC come obiettivi fondamentali per fermare la diffusione del cancro, sottolineando la capacità di Parsortix di superare i limiti spaziali e temporali delle metodologie di biopsia tissutale convenzionali.
ANGLE plc (OTCQX:ANPCY), una empresa líder en biopsias líquidas, anunció una publicación importante en Nature Genetics realizada por investigadores del ETH de Zúrich que utilizaron el sistema Parsortix® de la compañía. El estudio investigó la diversidad genética en los grupos de células tumorales circulantes (CTC) en el cáncer de mama.
La investigación reveló que los grupos de CTC son hasta 100 veces más metastásicos que las CTC individuales, siendo la diseminación metastásica responsable de más del 90% de las muertes relacionadas con el cáncer. Se encontró una mayor prevalencia de grupos de CTC en tumores de alta complejidad, con algunas mutaciones exclusivas de células específicas dentro de los grupos, que podrían pasar desapercibidas en las biopsias tisulares tradicionales.
Los hallazgos posicionan a los grupos de CTC como objetivos cruciales para detener la propagación del cáncer, destacando la capacidad de Parsortix para superar las limitaciones espaciales y temporales de los métodos convencionales de biopsia tisular.
ANGLE plc (OTCQX:ANPCY)는 액체 생검 분야의 선도 기업으로, ETH 취리히 연구진이 회사의 Parsortix® 시스템을 활용해 Nature Genetics에 중요한 논문을 발표했다고 밝혔습니다. 이 연구는 유방암에서 순환 종양 세포(CTC) 클러스터의 유전적 다양성을 조사했습니다.
연구 결과, CTC 클러스터는 개별 CTC보다 최대 100배 더 전이성이 높으며, 전이 확산이 암 관련 사망의 90% 이상을 차지하는 것으로 나타났습니다. 또한 고복잡도 종양에서 CTC 클러스터의 유병률이 높았으며, 일부 돌연변이는 기존 조직 생검으로는 발견되지 않을 수 있는 특정 CTC 클러스터 내 세포에만 존재하는 것으로 밝혀졌습니다.
이 결과는 CTC 클러스터를 암 전이 차단의 핵심 표적으로 자리매김하며, Parsortix가 기존 조직 생검 방법의 공간적·시간적 한계를 극복할 수 있음을 강조합니다.
ANGLE plc (OTCQX:ANPCY), une entreprise leader dans le domaine de la biopsie liquide, a annoncé une publication importante dans Nature Genetics réalisée par des chercheurs de l'ETH Zurich utilisant le système Parsortix® de la société. L'étude a examiné la diversité génétique des amas de cellules tumorales circulantes (CTC) dans le cancer du sein.
La recherche a révélé que les amas de CTC sont jusqu'à 100 fois plus métastatiques que les CTC individuelles, la propagation métastatique étant responsable de plus de 90 % des décès liés au cancer. L'étude a trouvé une plus grande prévalence des amas de CTC dans les tumeurs à haute complexité, certaines mutations étant exclusives à des cellules spécifiques au sein des amas, pouvant être manquées par les biopsies tissulaires traditionnelles.
Les résultats positionnent les amas de CTC comme des cibles cruciales pour arrêter la propagation du cancer, soulignant la capacité de Parsortix à dépasser les limites spatiales et temporelles des méthodes conventionnelles de biopsie tissulaire.
ANGLE plc (OTCQX:ANPCY), ein führendes Unternehmen im Bereich der Flüssigbiopsie, gab eine bedeutende Veröffentlichung in Nature Genetics bekannt, die von Forschern der ETH Zürich unter Verwendung des Parsortix®-Systems des Unternehmens durchgeführt wurde. Die Studie untersuchte die genetische Vielfalt in zirkulierenden Tumorzell-Clustern (CTC) bei Brustkrebs.
Die Forschung zeigte, dass CTC-Cluster bis zu 100-mal metastatischer sind als einzelne CTCs, wobei die metastatische Ausbreitung für über 90% der krebsbedingten Todesfälle verantwortlich ist. Die Studie fand eine höhere Prävalenz von CTC-Clustern in Tumoren mit hoher Komplexität, wobei einige Mutationen ausschließlich in bestimmten Zellen innerhalb der CTC-Cluster vorkommen, die bei herkömmlichen Gewebebiopsien übersehen werden könnten.
Die Ergebnisse positionieren CTC-Cluster als entscheidende Ziele zur Verhinderung der Krebsverbreitung und heben die Fähigkeit von Parsortix hervor, die räumlichen und zeitlichen Beschränkungen herkömmlicher Gewebebiopsiemethoden zu überwinden.
- Publication in prestigious Nature Genetics validates Parsortix system's capabilities
- Research demonstrates unique advantage of Parsortix in detecting mutations missed by traditional tissue biopsies
- Study confirms Parsortix's effectiveness in investigating CTC clusters, which are 100x more metastatic than individual CTCs
- Technology currently limited to research use only, not approved for diagnostic procedures
New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer
GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of a peer-reviewed article in Nature Genetics by Professor Nicola Aceto's team at ETH Zurich, Switzerland. The study utilised the Parsortix® system to investigate the genetic diversity of CTC clusters.
Understanding the genetic diversity of CTC clusters is of clinical importance because these cells are the precursors of progressive disease and metastasis. Cancer is a highly dynamic process, and cells are known to diversify over time due to treatment selection pressure and the accumulation of genetic changes. This leads to the emergence and expansion of new subclones with distinct characteristics and varying abilities to survive and proliferate. This process is crucial because it drives cancer development, progression, resistance to therapy, and relapse and can help in understanding how to develop effective cancer treatments.
This publication provides evidence of genetic diversity in CTC clusters in breast cancer patient samples and preclinical mouse models. It includes the finding that some mutations were exclusive to specific cells within CTC clusters that could therefore be missed by a tissue biopsy. The research in mouse models reports a higher prevalence of CTC clusters in high-complexity tumours, with large CTC clusters associated with higher genetic diversity.
The genetic diversity reported in this publication points to CTC clusters as key contributors to genetic diversity in metastasis. The authors believe that genetic diversity within CTC clusters enhances their metastatic capability by increasing therapy resistance opportunities, evasion of immune cell attack, as well as adaptability and survival at a metastatic site. CTC clusters are therefore important targets to stop the spread of cancer given these are up to 100 times more metastatic than individual CTCs, with metastatic spread responsible for more than
The authors conclude that CTC clusters carry cells from different tumour clones, and that the assessment of CTCs and CTC clusters using the Parsortix system may provide insights into genetic diversity that overcomes the spatial and temporal limitations associated with traditional tissue biopsy.
ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are pleased to see the Parsortix system being used to progress understanding of the role of CTC clusters in cancer progression and specifically the role of genetic diversity in enhancing their metastatic ability. This work builds on the Aceto lab's pioneering investigation into understanding CTC clusters and targeted therapy to halt the spread of cancer by targeting CTC clusters."
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Berenberg (NOMAD and Broker) | +44 (0) 20 3207 7800 |
FTI Consulting |
|
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
What did the Nature Genetics study reveal about ANGLE's (ANPCY) Parsortix system?
How significant are CTC clusters in cancer progression according to ANGLE's (ANPCY) research?
What are the advantages of ANGLE's (ANPCY) Parsortix system over traditional tissue biopsies?
What is the current regulatory status of ANGLE's (ANPCY) Parsortix system?
How does ANGLE's (ANPCY) Parsortix technology contribute to cancer research?
